SEC Form 4 · accession 0001209191-15-027512

Insys Therapeutics, Inc. · INSY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Michael L Babich

Officer — President and CEO · Director

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 4:49 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001516479

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 16, 2015	M	30,000	$3.25	A	202,752	D
Common Stock	Mar 16, 2015	M	45,755	$2.36	A	248,507	D
Common Stock	Mar 16, 2015	M	1,845	$7.26	A	250,352	D
Common Stock^F2	Mar 16, 2015	S	8,224	$57.91	D	242,128	D
Common Stock^F3	Mar 16, 2015	S	23,500	$59.07	D	218,628	D
Common Stock^F4	Mar 16, 2015	S	13,546	$59.71	D	205,082	D
Common Stock^F5	Mar 16, 2015	S	2,330	$60.62	D	202,752	D
Common Stock	Mar 17, 2015	M	27,400	$7.26	A	230,152	D
Common Stock^F6	Mar 17, 2015	S	12,500	$57.21	D	217,652	D
Common Stock^F7	Mar 17, 2015	S	13,300	$58.12	D	204,352	D
Common Stock^F8	Mar 17, 2015	S	1,600	$58.95	D	202,752	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F9	$3.25	Mar 16, 2015	M	30,000	D	—	Mar 27, 2021	Common Stock	30,000	43,034	D
Stock Option (right to buy)^F10	$2.36	Mar 16, 2015	M	45,755	D	—	Dec 26, 2022	Common Stock	45,755	117,995	D
Stock Option (right to buy)^F13,F11,F12	$7.26	Mar 16, 2015	M	1,845	D	—	May 13, 2023	Common Stock	1,845	373,155	D
Stock Option (right to buy)^F12	$7.26	Mar 16, 2015	M	27,400	D	—	May 13, 2023	Common Stock	27,400	345,755	D

Explanation of responses

F1Includes 457 shares acquired by the Reporting Person on December 10, 2014 pursuant to the Issuer's ESPP.
F10The option vests in 36 equal monthly installments and will be fully vested and exercisable on December 27, 2015.
F11The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014
F12The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.
F13On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 125,000 additional options
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.44 to $58.41, inclusive.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to $59.45, inclusive.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.46 to $60.41, inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.46 to $60.86, inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.67 to $57.66, inclusive.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 to $58.70, inclusive.
F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.73 to $59.20, inclusive.
F9The option vests in 48 equal monthly installments and will be fully vested and exercisable on March 28, 2015.

Remarks

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.